Name: Beta Blockers Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH4688
Price: 4350 USD
Availability: InStock

Beta Blockers Market Size Share Growth Opportunities and Forecast 2022

Beta Blockers Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Beta-Blockers Market is Segmented By Type (Nonselective Agents, Selective Agents), By Indication(Angina Pectoris, Heart Failure, High Blood Pressure, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End-User (Automotive, Aerospace, Safety, Medical, Energy, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

<blockquote>
Beta Blockers Market&nbsp;is Expected to reach at a high&nbsp;<a href="https://www.datamintelligence.com/download-sample/beta-blockers-market">CAGR 4.29&nbsp;%</a> during the forecast period (2023-2030).
</blockquote>

Beta blockers, also known as beta-adrenergic blocking agents, reduce blood pressure. It is used to prevent, deal with or improve symptoms in people who&#39;ve abnormal coronary heart rhythm (arrhythmia), coronary heart failure, Chest ache (angina), coronary heart assaults, Migraine, sure varieties of tremors. It works by blocking the effects of the hormone epinephrine, also known as adrenaline.

Beta-Blockers Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			4.29%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type, By Indication, By Distribution Channel, By End-User, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/beta-blockers-market">Click here</a>

<h3>Beta-Blockers Market Dynamics</h3>

The increasing prevalence of hypertension in the geriatric population is expected to drive market growth.

According to the American College of Cardiology, Older adults are generally undertreated for high blood pressure, despite having the highest prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). Hypertension is a major modifiable risk factor for cardiovascular disease (CVD), and its prevalence and severity rise with age. According to the National Health and Nutrition Examination Survey (NHANES) in the United States, hypertension affects 70% of persons over 65.&nbsp;As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is predicted to rise to 20% by 2050. Moreover, huge investment in R&amp;D, high prevalence and incidence of cardiovascular diseases have increased the demand for beta blockers drugs due to which the market is expected to drive in the forecast period.

Restraint:

Along with its needed effects, a medicine may cause some unwanted effects. Beta-blockers slowdown heart rate. This can trigger symptoms associated with low blood pressure (hypotension). In addition, it includes an upset stomach, nausea, diarrhea or constipation, and some people report erectile dysfunction when taking beta-blockers. This is a common side effect with medications that lower blood pressure. These are some factors that the market is expected to get hampered in the forecast period.

<h3>Beta Blockers Market - Industry Analysis</h3>

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Hypertension is one of the most common morbidities in COVID-19. Beta-blockers are widely used as one of the most common antihypertensive agents. It reduces the risk of proarrhythmia by suppressing sympathetic-mediated triggers, the functioning reentrant substrate, and the rates of the SA and AV nodes. In addition to this main benefit, as beta-adrenergic blockers, these drugs can block the gate of SARS-CoV-2 entry through negative regulation on the juxtaglomerular cells in the kidneys, reducing the activity of both arms of the RAAS pathway, thus lowering the ACE2 levels. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.

<h3>Beta-Blockers Market Segment Analysis</h3>

Nonselective Agents segment is expected to hold the largest market share in beta blockers market.

The non-selective agents&#39; segment accounted for the largest market share in 2020. Non-selective beta-blockers block &beta;1 receptors beta-2 (&beta;2) receptors in the body. These receptors affect how tight or relaxed blood vessels and airways are. Some non-selective beta-blockers can also have alpha-blocking effects. These have a larger effect on lowering blood pressure. For instance, it includes Propranolol (Inderal), Nadolol (CorGard), Pindolol (Visken), Penbutolol (Levatol), Sotalol (Betapace) and Others.

Moreover, some beta-blockers also come in combination tablets or eye drops, where the beta-blocker is combined with another type of medication that treats the same condition, and three beta-blockers are best for heart failure: carvedilol, metoprolol succinate (the long-acting form of metoprolol), and bisoprolol. These beta-blockers have been shown to lower your risk of dying from heart failure complications. Thus, the market is expected to hold the largest market share in the forecast period from the above statements.

<h3>Beta-Blockers Market Geographical Analysis</h3>

North America region holds the largest market share in the global beta blockers market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of cardiovascular diseases, huge investment in R&amp;D, increasing aged population, well-established infrastructure and increased demand for beta-blockers drugs are some factors that the market is expected to boost in the forecast period. For instance, According to the American Heart Association, heart disease and stroke&nbsp;are caused by unhealthy diets, physical inactivity, tobacco use, and harmful alcohol usage. Individuals may experience high blood pressure, high blood glucose, high blood lipids, and overweight or obesity due to behavioral risk factors. Twice as many people died in 2020 of heart disease (690,8820 as from COVID-19 (345,323). This doesn&#39;t even include another 159,150 who died from a stroke and another 106,106 from diabetes (mostly type 2), which have the same risk factors as heart disease. Heart disease deaths increased by 4.8%, the largest increase in heart disease deaths since 2012. Therefore, it has increased the demand for beta blockers, due to which the North American region is expected to hold the largest market share in the forecast period.

<h3>Beta-Blockers Market Competitive Landscape</h3>

Major key players in the beta blockers market are Pfizer, Neon Healthcare, Novartis, Mercury Laboratories Ltd., Bayer HealthCare Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Midas Pharma GmbH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , Global Calcium PVT LTD, Baxter and AbbVie Inc.

Bayer HealthCare Pharmaceuticals Inc.:

Bayer is a German multinational pharmaceutical and Life Sciences Company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer&#39;s business areas include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals division of Bayer focuses on prescription products for women&rsquo;s healthcare, cardiology, oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit, which markets contrast-enhanced diagnostic imaging equipment and the necessary contrast agents. Moreover, in 2020, the Bayer Group comprised 385 consolidated companies in 83 countries, and in 2020 alone, the company invested nearly &euro;2 billion in research and development.

Product Portfolio:

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Beta-Blockers Market?

Beta-Blockers Market is expected to grow at a&nbsp;CAGR of 4.29%&nbsp;during the forecasting period 2023-2030.

Which region controlled the global market during 2023-2030?

North America&nbsp;region Controls&nbsp;the&nbsp;Beta-Blockers Market&nbsp;during 2023-2030.

Which is the fastest growing region in the Beta-Blockers Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/pet-food-market">Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/organic-pet-food-market">Organic Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/freeze-dried-pet-food-market">Freeze-Dried Pet Food Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Indication</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>The increasing prevalence of hypertension in the geriatric population is expected to drive market growth.</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects associated with the beta blockers drugs are expected to hamper the market growth.</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type Segment</li>
		</ol>
		</li>
		<li>Nonselective Agents*
		<ol>
			<li>Propranolol (Inderal)</li>
			<li>Nadolol (CorGard)</li>
			<li>Pindolol (Visken)</li>
			<li>Penbutolol (Levatol)</li>
			<li>Sotalol (Betapace)</li>
			<li>Others</li>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Selective Agents
		<ol>
			<li>Atenolol</li>
			<li>Betaxolol</li>
			<li>Esmolol</li>
			<li>Nebivolol</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Indication</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Attractiveness Index, By Indication Segment</li>
		</ol>
		</li>
		<li>Angina Pectoris*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Heart&nbsp;Failure</li>
		<li>High Blood Pressure</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>Hospital Pharmacy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Retail Pharmacy</li>
		<li>Online Pharmacy</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>List of Key Companies to Watch</li>
	</ol>
	</li>
	<li>
	<h3>Global Beta Blockers Market- Company Profiles</h3>

	<ol>
		<li>Pfizer*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Neon Healthcare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Novartis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Mercury Laboratories Ltd.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Bayer HealthCare Pharmaceuticals Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Teva Pharmaceuticals USA, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Midas Pharma GmbH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Global Calcium PVT LTD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Baxter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>AbbVie Inc.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table1 Global Beta Blockers Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table2 Global Beta Blockers Market Value, By Indication, 2021, 2025 &amp; 2029 ($ Million)

Table3 Global Beta Blockers Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table4 Global Beta Blockers Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table5 Global Beta Blockers Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table6 Global Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table7 Global Beta Blockers Market Value, By Indication, 2021, 2025 &amp; 2029 ($ Million)

Table8 Global Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table9 Global Beta Blockers Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table10 Global Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table11 Global Beta Blockers Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table12 Global Beta Blockers Market Value, By Region, 2019-2029 ($ Million)

Table13 North America Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table14 North America Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table15 North America Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table16 North America Beta Blockers Market Value, By Country, 2019-2029 ($ Million)

Table17 South America Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table18 South America Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table19 South America Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table20 South America Beta Blockers Market Value, By Country, 2019-2029 ($ Million)

Table21 Europe Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table22 Europe Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table23 Europe Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table24 Europe Beta Blockers Market Value, By Country, 2019-2029 ($ Million)

Table25 Asia-Pacific Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table26 Asia-Pacific Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table27 Asia-Pacific Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table28 Asia-Pacific Beta Blockers Market Value, By Country, 2019-2029 ($ Million)

Table29 Middle East &amp; Africa Beta Blockers Market Value, By Type, 2019-2029 ($ Million)

Table30 Middle East &amp; Africa Beta Blockers Market Value, By Indication, 2019-2029 ($ Million)

Table31 Middle East &amp; Africa Beta Blockers Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table32 Pfizer: Overview

Table33 Pfizer: Product Portfolio

Table34 Pfizer: Key Developments

Table35 Neon Healthcare: Overview

Table36 Neon Healthcare: Product Portfolio

Table37 Neon Healthcare: Key Developments

Table38 Novartis: Overview

Table39 Novartis: Product Portfolio

Table40 Novartis: Key Developments

Table41 Mercury Laboratories Ltd.: Overview

Table42 Mercury Laboratories Ltd.: Product Portfolio

Table43 Mercury Laboratories Ltd.: Key Developments

Table44 Bayer HealthCare Pharmaceuticals Inc.: Overview

Table45 Bayer HealthCare Pharmaceuticals Inc.: Product Portfolio

Table46 Bayer HealthCare Pharmaceuticals Inc.: Key Developments

Table47 Teva Pharmaceuticals USA, Inc.: Overview

Table48 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table49 Teva Pharmaceuticals USA, Inc.: Key Developments

Table50 Midas Pharma GmbH: Overview

Table51 Midas Pharma GmbH: Product Portfolio

Table52 Midas Pharma GmbH: Key Developments

Table53 Global Calcium PVT LTD: Overview

Table54 Global Calcium PVT LTD: Product Portfolio

Table55 Global Calcium PVT LTD: Key Developments

Table56 Baxter: Overview

Table57 Baxter: Product Portfolio

Table58 Baxter: Key Developments

Table59 AbbVie Inc.: Overview

Table60 AbbVie Inc.: Product Portfolio

Table61 AbbVie Inc.: Key Developments

List of Figures

Figure1 Global Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure2 Global Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure3 Global Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure4 Global Beta Blockers Market Share, By Region, 2021 &amp; 2029 (%)

Figure5 Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure6 Global Beta Blockers Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure7 Nonselective Agents: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure8 Selective Agents: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure9 Global Beta Blockers Market Y-o-Y Growth, By Indication, 2021-2029 (%)

Figure10 Angina Pectoris: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure11 Heart&nbsp;Failure: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure12 High Blood Pressure: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure13 Others: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure14 Global Beta Blockers Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)

Figure15 Hospital&nbsp;Pharmacy: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure16 Online&nbsp;pharmacy: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure17 Retail Pharmacy: Global Beta Blockers Market Value, 2019-2029 ($ Million)

Figure18 Global Beta Blockers Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure19 North America Beta Blockers Market Value, 2019-2029 ($ Million)

Figure20 North America Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure21 North America Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure22 North America Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure23 North America Beta Blockers Market Share, By Country, 2021 &amp; 2029 (%)

Figure24 South America Beta Blockers Market Value, 2019-2029 ($ Million)

Figure25 South America Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure26 South America Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure27 South America Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure28 South America Beta Blockers Market Share, By Country, 2021 &amp; 2029 (%)

Figure29 Europe Beta Blockers Market Value, 2019-2029 ($ Million)

Figure30 Europe Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure31 Europe Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure32 Europe Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure33 Europe Beta Blockers Market Share, By Country, 2021 &amp; 2029 (%)

Figure34 Asia-Pacific Beta Blockers Market Value, 2019-2029 ($ Million)

Figure35 Asia-Pacific Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure36 Asia-Pacific Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure37 Asia-Pacific Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure38 Asia-Pacific Beta Blockers Market Share, By Country, 2021 &amp; 2029 (%)

Figure39 Middle East &amp; Africa Beta Blockers Market Value, 2019-2029 ($ Million)

Figure40 Middle East &amp; Africa Beta Blockers Market Share, By Type, 2021 &amp; 2029 (%)

Figure41 Middle East &amp; Africa Beta Blockers Market Share, By Indication, 2021 &amp; 2029 (%)

Figure42 Middle East &amp; Africa Beta Blockers Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure43 Pfizer: Financials

Figure44 Neon Healthcare: Financials

Figure45 Novartis: Financials

Figure46 Mercury Laboratories Ltd.: Financials

Figure47 Bayer HealthCare Pharmaceuticals Inc.: Financials

Figure48 Teva Pharmaceuticals USA, Inc.: Financials

Figure49 Midas Pharma GmbH: Financials

Figure50 Global Calcium PVT LTD: Financials

Figure51 Baxter: Financials

Figure52 AbbVie Inc.: Financials